CODE DATE NTD							
PATENT	COOPERATION TREATY						
	PCT						
ANKOM 1 2 MAY 2005 GIPS							
	JIMINARY REPORT ON PATENTABILITY of the Patent Cooperation Treaty)						
ENTERED							
CHECK	T Article 36 and Rule 70)						
Applicant's or agent's file reference 100905-1 WO FOR FUR	THER ACTION See Form PCT/IPEA/416						
	filing date (day/month/year) Priority date (day/month/year)						
PCT/SE 2004/000487 30.03.							
International Patent Classification (IPC) or national class							
CO7D 213/30, A61K 31/44, A61	P 29/00						
Applicant							
AstraZeneca AB et al							
This report is the international preliminary exam Authority under Article 35 and transmitted to the second control of the secon	nination report, established by this International Preliminary Examining he applicant according to Article 36.						
2. This REPORT consists of a total of 5	sheets, including this cover sheet.						
This report is also accompanied by ANNEXES,	comprising:						
a. (sent to the applicant and to the Int	ternational Bureau) a total of sheets, as follows:						
sheets of the description, cl	aims and/or drawings which have been amended and are the basis of this report						
and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).							
beyond the disclosure in the	lier sheets, but which this Authority considers contain an amendment that goes e international application as filed, as indicated in item 4 of Box No. I and the						
Supplemental Box.							
b (sent to the International Bureau of	nly) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer						
readable form only, as indicated in Administrative Instructions).	the Supplemental Box Relating to Sequence Listing (see Section 802 of the						
4. This report contains indications relating to the f	ollowing items:						
Box No. I Basis of the report							
Box No. II Priority							
	f opinion with regard to novelty, inventive step and industrial applicability						
Box No. IV Lack of unity of inve							
Box No. V Reasoned statement to applicability; citation	applicability; citations and explanations supporting such statement						
Box No. VI Certain documents ci							
Box No. VII Certain defects in the	international application						
Box No. VIII Certain observations	on the international application						
Day Calain selled design	Date of completion of this report						
Date of submission of the demand	Date of completion of this report						
06.10.2004	08.04.2005						
Name and mailing address of the IPBA/SE	Authorized officer						
Patent- och registreringsverket							
BOX 5055 S-102 42 STOCKHOLM	Eva Johansson/MP						
P::1-N 46 0 667 72 00	Telephone No. ±46 8 782 25 00						

International application No.

PCT/SE 2004/000487

1. With regard to the lauguage, this report is based on the international application in the language in which it was file otherwise indicated under this item. This report is based on a translation from the original language into the following language which is the language of a translation furnished for the purposes of: International search (under Rules 12.3 and 23.1(b)) publication of the international application (under Rule 12.4) international preliminary examination (under Rules 55.2 and/or 55.3) 2. With regard to the elements of the international application, this report is based on (replacement sheets which h furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "original and are not annexed to this report): The international application as originally filed/furnished the description: pages	ave been ully filed" nished nished
which is the language of a translation furnished for the purposes of: international search (under Rules 12.3 and 23.1(b)) publication of the international application (under Rule 12.4) international preliminary examination (under Rules 55.2 and/or 55.3) 2. With regard to the elements of the international application, this report is based on (replacement sheets which he furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "original and are not annexed to this report): the international application as originally filed/furnished the description: pages	nished nished nished nished
publication of the international application (under Rules 55.2 and/or 55.3) 2. With regard to the elements of the international application, this report is based on (replacement sheets which h furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "original and are not annexed to this report): the international application as originally filed/furnished the description: pages	nished nished nished nished
international preliminary examination (under Rules 55.2 and/or 55.3) 2. With regard to the elements of the international application, this report is based on (replacement sheets which h furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "original and are not annexed to this report): the international application as originally filed/furnished the description: pages	nished nished nished nished
2. With regard to the elements of the international application, this report is based on (replacement sheets which h furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "original and are not annaxed to this report): the international application as originally filed/furnished the description: pages	nished nished nished nished
furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "original and are not annexed to this report): the international application as originally filed/furnished the description: pages	nished nished nished nished
the description: pages	nished
pages*	nished
pages* received by this Authority on pages* received by this Authority on received by this Authority on received by this Authority on pages as a mended (together with any statement) under Authority on pages* received by this Authority on received by this Authority on pages* received by this Authority on the description, pages the claims, Nos.	nished
the claims: pages	nished rticle 19
the claims: pages	nished rticle 19
pages* as originally filed/fur pages* as amended (together with any statement) under Ar pages* received by this Authority on pages* as originally filed/fur pages* as originally filed/fur pages* as originally filed/fur pages* received by this Authority on pages* received by this Authority on pages* received by this Authority on a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing. The amendments have resulted in the cancellation of: the description, pages the claims, Nos.	rticle 19
pages* as amended (together with any statement) under An pages* received by this Authority on as originally filed/fur pages* as originally filed/fur pages* received by this Authority on as originally filed/fur pages* received by this Authority on as equence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing. 3. The amendments have resulted in the cancellation of: the description, pages the claims, Nos	rticle 19
pages* received by this Authority on as originally filed/fur pages* as originally filed/fur pages* received by this Authority on as equence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing. 3. The amendments have resulted in the cancellation of: the description, pages the claims, Nos	
the drawings: pages as originally filed/fur pages* received by this Authority on pages* received by this Authority on pages* received by this Authority on a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing. 3.	
the drawings: pages as originally filed/fur pages* received by this Authority on pages* received by this Authority on a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing. The amendments have resulted in the cancellation of: the description, pages the claims, Nos	
pages* as originally filed/fur pages* received by this Authority on pages* received by this Authority on a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing. 3. The amendments have resulted in the cancellation of: the description, pages the claims, Nos	
pages* received by this Authority on received by this Authority on a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing. 3. The amendments have resulted in the cancellation of: the description, pages the claims, Nos	nished
pages* received by this Authority on a sequence listing and/or any related table(s) – see Supplemental Box Relating to Sequence Listing. 3. The amendments have resulted in the cancellation of: the description, pages the claims, Nos	
3. The amendments have resulted in the cancellation of: the description, pages the claims, Nos.	
the description, pages the claims, Nos	
the claims, Nos.	
the drawings, sheets/figs	
the sequence listing (specify):	
any table(s) related to the sequence listing (specify):	
4. This report has been established as if (some of) the amendments annexed to this report and listed below had made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental 70.2(c)).	i not been Box (Rule
the description, pages	
the claims, Nos.	
the drawings, sheets/figs	
the sequence listing (specify):	
any table(s) related to the sequence listing (specify):	
* If item 4 applies, some or all of those sheets may be marked "superseded."	

International application No.

PCT/SE 2004/000487

Box No. I	III Non-establishment of opinion	n with	regard to novelt	y, inventiv	e step and	industrial	applicability	<u> </u>
The quest	ions whether the claimed invention ap to have not been examined in respect o	ppears tof:	to be novel, to inv	olve an inv	ventive step	(to be not	n obvious), or	to be industrially
	the entire international application		.00				* *	
\boxtimes	claims Nos. 13, 14					· · · · · · · · · · · · · · · · · · ·		
becaus	ec:							
\boxtimes	the said international application, or relate to the following subject matter	the said	claims Nos. 1	3, 14	onal prelim	inary exa	mination (spec	ifo):
	PCT Rule 67.1. (iv)				•	•		
anir	mal body by surge				as wel	ll as	diagn	ostic
met	hods.		,					
			•		·			
:								
	the description, claims or drawings (a are so unclear that no meaningful opi	indicate	e particular eleme	ents below)	or said clai	ims Nos.		
•	are so unclear that no meaningful opi	unon a		pecijy ji				
						· ·		•
								• . •
:								
	the claims, or said claims Nos.			· 		· i	are so inadequ	ately supported
•	by the description that no meaningful	l opinic	on could be forme	ed.				
	no international search report has been	en estab	olished for said cl	laims Nos.				
	the nucleotide and/or amino acid seq Administrative Instructions in that:	uence l	isting does not o	omply with	the standar	rd provide	d for in Anne	C of the
	the written form		has not been fu	mished				
			does not compl	y with the	standard			•
	the computer readable form		has not been fu	mished			•	
			does not compl	•				
	the tables related to the nucleotide an the technical requirements provided to	nd/or an for in ti	nino acid sequen he Annex C-bis o	ce listing, i	if in compu inistrative I	ter readab natruction	le form only, ons.	lo not comply wi
	See Supplemental Box for further de	tails.						
			•					

International application No.

PCT/SE 2004/000487

citations and explanat	ions support	ng such statement	
Novelty (N)	Claims Claims	1-12, 15	YES NO
Inventive step (IS)	Claims Claims	1-12. 15	YE.
Industrial applicability (IA)	Claims Claims	1-12. 15	YE:

2. Citations and explanations (Rule 70.7)

The claimed invention relates to novel 6-substituted 2-aminopyridine derivates for the treatment or prophylaxis of human diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial especially inflammatory diseases, a process for their preparation and compositions containing them.

The following documents are cited in the search report:

D1 WO 9618617 A1

D2 WO 9618616 A1

D3 US 4590167 A1

D4 STN International, File CAPLUS, CAPLUS accession no. 1980:18197, Document no. 92:18197

D1 is regarded as being the closest prior art to the subjectmatter of claim 1-12 and 15 and discloses substituted 2acylamino-pyridines as inhibitors of nitric oxide synthase. The claimed compounds differ structurally from the known compounds.

Thus, the cited documents represent the general state of the art.

The invention defined in claims 1-12 and 15 is not disclosed by any of these documents.

The cited prior art does not give any indication that would lead a person skilled in the art to the claimed compounds as inhibitors of nitric oxide synthase.

Therefore, the claimed invention is not obvious to a person

. . . / . . .

International application No.

PCT/SE 2004/000487

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of: BOX $\,V\,$

skilled in the art.

Consequently, the cited documents only disclose the general state of the art, and are not considered to be of particular relevance.

Accordingly, the invention defined in claims 1-12 and 15 is novel and is considered to involve an inventive step. The invention is industrially applicable.